LivaNova LIVN Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Net revenue by Business | |||||
| Cardiopulmonary | $785.39M+14.9% | $683.51M+13.1% | $604.11M+17.5% | $514.2M+6.5% | |
| Neuromodulation | $592.81M+7.0% | $554.22M+6.6% | $519.71M+9.0% | $476.99M+4.6% | |
| Operating Income by Business | |||||
| Cardiopulmonary | $108.3M— | —— | $26.41M+135% | $11.25M+275% | |
| Neuromodulation | $215.47M— | —— | $153.38M-11.2% | $172.78M+1.9% | |
| Total Assets by Business | |||||
| Cardiopulmonary | $4.02B+7.3% | $3.74B+1.4% | $3.69B+7.0% | $3.45B— | |
| Neuromodulation | $2.56B-0.3% | $2.57B-0.3% | $2.58B-0.7% | $2.59B-0.1% | |
| Selling, general, and administrative by Business | |||||
| Cardiopulmonary | $229.78M+3.8% | $221.32M+6.9% | $207M+22.8% | $168.6M— | |
| Neuromodulation | $202.6M+8.0% | $187.65M+7.1% | $175.27M+10.3% | $158.98M— | |
| Foreign currency translation adjustment by Business | |||||
| Cardiopulmonary | $42.83M+230% | -$32.94M-333% | $14.15M+150% | -$28.21M-23.8% | |
| Neuromodulation | $0— | $0— | $0— | $0— | |
| Cost of Sales by Business | |||||
| Cardiopulmonary | $381.71M+14.2% | $334.33M+9.1% | $306.36M+21.6% | $251.86M— | |
| Neuromodulation | $55.82M+11.1% | $50.24M0.0% | $50.21M+58.8% | $31.62M— | |
| R&D by Business | |||||
| Cardiopulmonary | $65.74M+24.3% | $52.9M+16.9% | $45.26M+7.5% | $42.11M— | |
| Neuromodulation | $118.92M-1.7% | $121.03M-14.1% | $140.84M+24.0% | $113.62M— | |
| 3T litigation provision by Business | |||||
| Cardiopulmonary | $4.38M-77.8% | $19.69M-43.0% | $34.52M0.0% | $34.52M-9.4% | |
| Neuromodulation | $0— | $0— | $0— | $0— | |
| CapEx by Business | |||||
| Cardiopulmonary | $44.51M+58.4% | $28.09M+25.6% | $22.37M+61.8% | $13.83M-6.7% | |
| Neuromodulation | $15.83M+273% | $4.24M+253% | $1.2M+225% | $369K+106% | |
| Goodwill by Business | |||||
| Cardiopulmonary | $1.54B+4.7% | $1.47B-2.2% | $1.51B+1.9% | $1.48B— | |
| Neuromodulation | $1.6B0.0% | $1.6B0.0% | $1.6B0.0% | $1.6B0.0% | |
| Net revenue by Geography | |||||
| Europe | $269.18M+22.3% | $220.03M+2.4% | $214.79M+20.1% | $178.8M-11.3% | |
| Rest of World | $379.3M+12.1% | $338.32M+11.4% | $303.71M+11.9% | $271.45M+3.4% | |
| United States | $739.57M+6.4% | $695.08M+9.5% | $635.04M+11.1% | $571.56M0.0% | |
| Property, Plant and Equipment, Net by Geography | |||||
| Europe | $487.95M+39.2% | $350.47M+8.9% | $321.82M+4.3% | $308.42M-11.2% | |
| Rest of World | $56.46M+95.4% | $28.9M+53.5% | $18.82M+10.6% | $17.01M-19.3% | |
| United States | $289.81M+7.1% | $270.5M+3.5% | $261.47M+3.7% | $252.19M+1.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does LivaNova break its business down?
- LivaNova (LIVN) reports net revenue by business across 2 parts — Cardiopulmonary and Neuromodulation. Each is extracted from the segment footnotes and tracked over time.
- Where does LivaNova's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in LivaNova's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.